ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0473

Comprehensive Assessment of Cranial and Orbital Vasculature on MRI in Patients with Giant Cell Arteritis

Rennie Rhee, Shubhasree Banerjee, Vatsal Bhatt, Madhura Tamhankar, Naomi Amudala, Sherry Chou, Morgan Burke, Laurie Loevner, Peter Merkel and Jae Song, University of Pennsylvania, Philadelphia, PA

Meeting: ACR Convergence 2022

Keywords: Disease Activity, Eye Disorders, giant cell arteritis, Magnetic resonance imaging (MRI), Vasculitis

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: Vasculitis – Non-ANCA-Associated and Related Disorders Poster I: Giant Cell Arteritis

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Vessel wall MRI depicts changes consistent with arterial wall inflammation. Unlike temporal artery biopsy, MRI visualizes several full-length cranial arteries in a single scan mitigating sampling error. MRI also evaluates orbital arteries posterior to the ocular globe, an area not visualized by ophthalmologic exam. While previous studies demonstrated good diagnostic performance of MRI in evaluating temporal arteries in giant cell arteritis (GCA), little is known about changes to other cranial and orbital arteries. This study compared MRI enhancement of multiple cranial and orbital arteries in patients with GCA versus controls.

Methods: Patients with suspected new or relapsing cranial GCA who underwent vessel wall brain and/or orbital MRI at presentation were included in the study. A clinical diagnosis of active ocular GCA or non-ocular GCA was determined by a rheumatologist and/or ophthalmologist and confirmed retrospectively. All MR images were scored by a single radiologist blinded to clinical data. Semi-quantitative integer scores of MRI enhancement were determined: cranial arteries were each scored 0, 1, 2, or 3 (score 2-3 defined as abnormal) and orbital structures were each scored 0, 1, or 2 (score 1-2 defined as abnormal). Fisher’s exact test was used for group comparisons and Spearman’s rank for correlations between MRI scores and ESR/CRP levels.

Results: 36 patients had cranial arteries visualized on vessel wall MRI (final clinical diagnosis: 13 with GCA; 23 non-GCA) and 40 patients had orbital structures visualized on MRI (final clinical diagnosis: 4 ocular GCA [confirmed on fundoscopy]; 10 non-ocular GCA; 26 non-GCA). No patient in the non-GCA group had abnormal cranial artery enhancement. Among patients diagnosed with GCA, enhancement was observed in multiple arteries known to be affected by GCA with the most common being the temporal arteries (80%) and occipital arteries (58%)(Figure 1). MRI depicted multiple enhancing orbital structures which corresponded with vascular territories known to contribute to ischemic optic neuropathy in GCA (Figure 2). Orbital enhancement was observed in both ocular and non-ocular GCA (all P > 0.05). Example MR images are shown in Figure 3 including a patient with monocular vision loss who had bilateral orbital enhancement on MRI. Higher CRP levels were associated with higher composite and mean orbital MRI scores (ρ = 0.7, P = 0.02); no associations were found with cranial artery scores and ESR or CRP. In four (11%) of the 36 brain MRIs, a separate clinically important abnormality was found including stroke, malignancy, or aneurysm.

Conclusion: Beyond the temporal arteries, MRI identifies abnormal enhancement of multiple cranial and orbital arteries in patients with GCA all in a single scan. Compared to temporal artery ultrasound and biopsy, cross-sectional MR imaging examines a broader range of arterial territories including the most feared complication of orbital involvement. Future applications of vessel wall MRI in GCA may include risk stratification (e.g., subclinical orbital involvement), disease classification, disease activity assessment, and understanding disease pathophysiology.

Supporting image 1

Supporting image 2

Supporting image 3


Disclosures: R. Rhee, None; S. Banerjee, None; V. Bhatt, None; M. Tamhankar, None; N. Amudala, None; S. Chou, None; M. Burke, None; L. Loevner, Guerbet; P. Merkel, AbbVie, AstraZeneca, Boeringher-Ingelheim, Bristol-Myers Squibb, ChemoCentryx, Forbius, Genentech/Roche, Genzyme/Sanofi, GlaxoSmithKline, InflaRx, Neutrolis, Takeda, CSL Behring, Dynacure, EMDSerono, Immagene, Jannsen, Kiniksa, Magenta, Novartis, Pfizer, Q32, Regeneron, Sparrow, Eicos, Electra, Kyverna, UpToDate; J. Song, None.

To cite this abstract in AMA style:

Rhee R, Banerjee S, Bhatt V, Tamhankar M, Amudala N, Chou S, Burke M, Loevner L, Merkel P, Song J. Comprehensive Assessment of Cranial and Orbital Vasculature on MRI in Patients with Giant Cell Arteritis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/comprehensive-assessment-of-cranial-and-orbital-vasculature-on-mri-in-patients-with-giant-cell-arteritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comprehensive-assessment-of-cranial-and-orbital-vasculature-on-mri-in-patients-with-giant-cell-arteritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology